Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
AC Immune SA
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 2.67 · gapped below the open, then crossed back over prior close. High/low 2.67 at 4:00 pm ET, 2.61 at 10:00 am ET.
AC Immune SA has 0 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either AC Immune SA’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a supplier of AC Immune SA. Suppliers appear here when AC Immune SA names them in its own annual report, or when a company names AC Immune SA as a customer in theirs.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In December 2018, we entered into an exclusive, worldwide licensing agreement with Eli Lilly and Company (Lilly) to research and develop Morphomer Tau small molecules for the treatment of AD and other neurodegenerative diseases. Per the terms of the agreement, the Company received an initial upfront payment of CHF 80 million in Q1 2019 for the rights granted by the Company to Lilly.”
FILING20-F0001104659-26-027342cik 0001651625
“In December 2014, we entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), part of a Johnson & Johnson company, to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other tauopathies.”
FILING20-F0001104659-26-027342cik 0001651625
“In May 2014 (as amended in June 2022), we entered into a license and collaboration agreement with Lantheus (formerly LMI and formerly Piramal Imaging SA) covering our Tau-PET Imaging tracers.”
FILING20-F0001104659-26-027342cik 0001651625
“In May 2024, we entered into an exclusive option and license agreement with Takeda for our active immunotherapies targeting Abeta, including ACI-24.060.”
FILING20-F0001104659-26-027342cik 0001651625
Watchlist prices, news filtered to it, and its next report on your desk.
ACIU (AC Immune SA) has 0 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LLY +0.24%, in healthcare.